157 related articles for article (PubMed ID: 36219689)
21. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
[TBL] [Abstract][Full Text] [Related]
22. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
24. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
26. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
[TBL] [Abstract][Full Text] [Related]
27. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Wang J; Li T; Wang B
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
[TBL] [Abstract][Full Text] [Related]
28. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
29. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
[TBL] [Abstract][Full Text] [Related]
30. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Yu Y; Wang A; Wang S; Sun Y; Chu L; Zhou L; Yang X; Liu X; Sha C; Sun K; Xu L
Mol Pharm; 2022 Apr; 19(4):1219-1229. PubMed ID: 35262365
[TBL] [Abstract][Full Text] [Related]
32. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
33. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
35. A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Brandt B; Németh M; Berta G; Szünstein M; Heffer M; Rauch TA; Pap M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175636
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
37. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
38. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
39. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
40. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
